Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study

Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease. Our study aimed to assess the outcomes of women with HER2-positive T1a/bN0 breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Sanji, Hendry, Jace, Le, Duc, Mondal, Prosanta K., Sami, Amer, Chalchal, Haji, Haider, Kamal, Ahmed, Osama, El-Gayed, Ali, Wright, Philip, Pauls, Mehrnoosh, Johnson, Kate, Ahmed, Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776836/
https://www.ncbi.nlm.nih.gov/pubmed/35058536
http://dx.doi.org/10.1038/s41598-022-05209-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776836/
https://www.ncbi.nlm.nih.gov/pubmed/35058536
http://dx.doi.org/10.1038/s41598-022-05209-8

Ejemplares similares